Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214565 · ClinicalTrials.gov registry record · Phase 3
GALLANT 6 Tesaglitazar vs. Pioglitazone
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,450
- Enrollment target
NCT00214565: Clinical Trial Phase 3 study, sponsored by AstraZeneca.
NCT00214565 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1,450 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00214565, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,450 participants
- Enrollment target
Study Summary
This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, 6 week placebo single blind run in period followed by a 24-week double blind treatment period and a 3-week follow-up period.
Interventions
- DRUG Galida
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,450 participants |
| Start Date | 2004-08 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Why NCT00214565 stopped before completion
NCT00214565 is an interventional study that assigns participants to a tested intervention. Its 1,450 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher).
The record links to 0 conditions, and to 1 intervention - of which Galida is the first listed.
NCT00214565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00214565 about?
NCT00214565 is a clinical study titled "GALLANT 6 Tesaglitazar vs. Pioglitazone". This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, ...
What is the current status of trial NCT00214565?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,450 participants. The study started on 2004-08. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00214565?
The interventions under investigation include: Galida (DRUG).
Who is sponsoring clinical trial NCT00214565?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00214565's enrollment target sits among peer trials
1,450 166th of 2000 higher than 1,834 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
- NCT05910268 · 1,450 participants · NA
Peru Decentralized HIV Care
- NCT06305312 · 1,450 participants · NA
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia